Independent directory Public ClinicalTrials.gov records United States
ClinicalTrials.gov record
Completed Phase 3 Interventional Results available

A Study of ALKS 5461 for the Treatment of Major Depressive Disorder (MDD) - the FORWARD-4 Study

ClinicalTrials.gov ID: NCT02158533

Public ClinicalTrials.gov record NCT02158533. Field values are reproduced from the official study page; the official ClinicalTrials.gov record remains the source of truth for eligibility, enrollment, and contact information.

ClinicalTrials.gov public records Last synced Jul 23, 2026, 11:48 PM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Official title

A Phase 3 Efficacy and Safety Study of ALKS 5461 for the Adjunctive Treatment of Major Depressive Disorder (the FORWARD-4 Study)

Study identification

NCT ID
NCT02158533
Recruitment status
Completed
Study type
Interventional
Phase
Phase 3
Lead sponsor
Alkermes, Inc.
Industry
Enrollment
385 participants

Conditions and interventions

Interventions

  • High Dose ALKS 5461 Drug
  • Low Dose ALKS 5461 Drug
  • Placebo Drug

Drug

Eligibility (public fields only)

Age range
18 Years to 70 Years
Sex
All
Healthy volunteers
Healthy volunteers not accepted

This page does not interpret eligibility. Detailed inclusion and exclusion criteria are on the official ClinicalTrials.gov record.

Study timeline

Start date
Apr 30, 2014
Primary completion
Nov 30, 2015
Completion
Nov 30, 2015
Last update posted
Aug 13, 2019

2014 – 2015

United States locations

U.S. sites
42
U.S. states
19
U.S. cities
40
Facility City State ZIP Site status
Alkermes Investigational Site Birmingham Alabama 35226
Alkermes Investigational Site Tucson Arizona 85712
Alkermes Investigational Site Carson California 90746
Alkermes Investigational Site National City California 91950
Alkermes Investigational Site Orange California 92868
Alkermes Investigational Site Sherman Oaks California 91403
Alkermes Investigational Site Torrance California 90502
Alkermes Investigational Site Upland California 91786
Alkermes Investigational Site Hartford Connecticut 06106
Alkermes Investigational Site Norwich Connecticut 06360
Alkermes Investigational Site Coral Springs Florida 33067
Alkermes Investigational Site Gainesville Florida 32607
Alkermes Investigational Site Lauderhill Florida 33319
Alkermes Investigational Site Orlando Florida 32801
Alkermes, Investigational Site Alpharetta Georgia 30005
Alkermes Investigational Site Decatur Georgia 30030
Alkermes Investigational Site Chicago Illinois 60640
Alkermes Investigational Site Joliet Illinois 60435
Alkermes Investigational Site Skokie Illinois 60076
Alkermes Investigational Site Newburgh Indiana 47630
Alkermes Investigational Site Valparaiso Indiana 46383
Alkermes Investigational Site Owensboro Kentucky 42301
Alkermes Investigational Site Baltimore Maryland 21208
Alkermes Investigational Site Baltimore Maryland 21285
Alkermes Investigational Site Berlin New Jersey 08009
Alkermes Investigational Site Brooklyn New York 11241
Alkermes Investigational Site Mount Kisco New York 10549
Alkermes Investigational Site New York New York 10128
Alkermes Investigational Site Staten Island New York 10305
Alkermes Investigational Site Canton Ohio 44718
Alkermes Investigational Site Dayton Ohio 45417
Alkermes Investigational Site Oklahoma City Oklahoma 73103
Alkermes Investigational Site Oklahoma City Oklahoma 73112
Alkermes Investigational Site Allentown Pennsylvania 18104
Alkermes Investigational Site Media Pennsylvania 19063
Alkermes Investigational Site Philadelphia Pennsylvania 19107
Alkermes Investigational Site Lincoln Rhode Island 02865
Alkermes Investigational Site Austin Texas 78731
Alkermes Investigational Site Houston Texas 77081
Alkermes Investigational Site San Antonio Texas 78229
Alkermes Investigational Site Woodstock Vermont 05091
Alkermes Investigational Site Middleton Wisconsin 53562

Site contact phone numbers, emails, and investigator names are intentionally not displayed here. Open the official ClinicalTrials.gov record for site contact information.

Non-U.S. locations

This page focuses on the U.S. directory. The official record also lists 7 non-U.S. sites.

About this trial record page

What this page shows
Public field values for ClinicalTrials.gov record NCT02158533, including study identification, conditions, interventions, eligibility (age, sex, healthy volunteer), timeline, and U.S. site list.
What this page does not do
No medical advice, eligibility judgments, treatment recommendations, study quality scoring, or AI-generated medical summaries. No site contact phone numbers, emails, or investigator names.
Where the data comes from
Sourced from the official ClinicalTrials.gov public API. The official record is the source of truth.
Last refresh
Last update posted Aug 13, 2019 · Synced Jul 23, 2026

Related: full search, browse by condition, browse by drug or therapy, browse by sponsor, browse by U.S. city.

Open the official record

The complete protocol, eligibility criteria, and contact information for NCT02158533 live on ClinicalTrials.gov.

View official ClinicalTrials.gov record →